# US 2023/0404974 A1 · Transmucosal dephosphorylated psychoactive alkaloid composition and preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404974 A1
- Document ID: US20230404974A1
- Status: Published application
- Kind: A1
- Application number: 18/238,478
- Filed: 2023-08-26
- Published: 2023-12-21
- Earliest claimed: 2020-12-28
- Assignees: Psilo Scientific Ltd.
- Applicants: Psilo Scientific Ltd.
- Inventors: Ryan Moss; Benjamin Lightburn; Lisa Ranken
- Web page: https://patentgrep.com/patent/US20230404974A1

## CPC

- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/2095: {Tabletting processes}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 36/078: {Psilocybe}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 2236/15: involving mechanical treatment, e.g. chopping up, cutting or grinding
- A61K 2236/17: involving drying, e.g. sun-drying or wilting
- A61K 2236/39: Complex extraction schemes, e.g. fractionation or repeated extraction steps
- A61K 2236/53: Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

## Claims

### Claim 1

A transmucosal psychoactive alkaloid composition consisting of, by weight:
1-40% of a dephosphorylated psychoactive alkaloid extract comprising psychoactive alkaloid that is psilocin, bufotenine, bufotenidine, norpsilocin, 4-hydroxytryptamine, N,N,N-trimethyl-4-hydroxytryptamine or any combination selected therefrom;
1-50% of mucoadhesive polymer;
10-65% of carrier; and
0-30.5% in total of one or more excipients other than the mucoadhesive polymer and the carrier.

### Claim 2 (depends on 1)

The composition of claim 1, wherein a content of the psychoactive alkaloid in the dephosphorylated psychoactive alkaloid extract is in a range from 0.1% to 99% by weight.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the content of the psychoactive alkaloid in the dephosphorylated psychoactive alkaloid extract is defined as a percentage up to two decimal places.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the dephosphorylated psychoactive alkaloid extract comprises naturally occurring substances from the group consisting of fats, sugars, carbohydrates, chitin, chitosan, minerals, waxes and proteins.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the naturally occurring substances are present in the dephosphorylated psychoactive alkaloid extract in a concentration ranging from 1% to 99.9% by weight.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the dephosphorylated psychoactive alkaloid extract has been through a purification process to remove one or more impurities of the group consisting of sugars, carbohydrates, chitin, chitosan, fats, minerals, waxes and proteins to result in a purified extract, and a content of the psychoactive alkaloid in the purified extract is in a range from 10% to 99% by weight.

### Claim 7 (depends on 1)

The composition of claim 1, comprising 15-35% by weight of the mucoadhesive polymer.

### Claim 8 (depends on 1)

The composition of claim 1, comprising 25-40% by weight of the carrier.

### Claim 9 (depends on 1)

The composition of claim 1, in a powder or a granular form.

### Claim 10 (depends on 1)

The composition of claim 1, in a tablet form.

### Claim 11 (depends on 1)

The composition of claim 1, comprising 10-50% by weight of the carrier.

### Claim 12 (depends on 1)

The composition of claim 1, wherein one of the one or more excipients is a binder and the composition comprises 5-20% by weight of the binder.

### Claim 13 (depends on 12)

The composition of claim 12, comprising 5-10% by weight of the binder.

### Claim 14 (depends on 1)

The composition of claim 1, wherein one of the one or more excipients is a preservative and the composition comprises 1-5% by weight of the preservative.

### Claim 15 (depends on 14)

The composition of claim 14, comprising 3-5% by weight of the preservative.

### Claim 16 (depends on 1)

The composition of claim 1, wherein:
one of the one or more excipients is a bioavailability agent selected from the group consisting of beta cyclodextrin, alpha cyclodextrin, piperine, citric acid and beta-carbolines; and
the composition comprises up to 5% by weight of the bioavailability agent.

### Claim 17 (depends on 16)

The composition of claim 16, comprising 0.5-2% by weight of the bioavailability agent.

### Claim 18 (depends on 1)

The composition of claim 1, wherein one of the one or more excipients is a flavor agent and the composition comprises up to 0.5% by weight of the flavor agent.

### Claim 19 (depends on 18)

The composition of claim 18, comprising 0.1% by weight of the flavor agent.

### Claim 20 (depends on 1)

The composition of claim 1, wherein one of the one or more excipients is a disintegrant and the composition comprises the disintegrant.

### Claim 21

A process for obtaining a transmucosal psychoactive alkaloid composition, the process comprising:
mixing a dried powdered psychoactive alkaloid source with an acidified solvent to obtain a slurry, wherein:
the dried powdered psychoactive alkaloid source comprises psilocin, bufotenine, bufotenidine, norpsilocin, 4-hydroxytryptamine, N,N,N-trimethyl-4-hydroxytryptamine, psilocybin, baeocystin, norbaeocystin, aeruginascin or any combination selected therefrom; and
the acidified solvent has a pH of 3.5 or lower and is a mixture of an acid and a solvent that is a C1-C4 primary aliphatic alcohol, a C3-C4 ketone, water or any combination selected therefrom;
filtering the slurry to obtain a psychoactive alkaloid liquid;
adjusting the pH of the psychoactive alkaloid liquid to a pH ranging from 3.5-4.5;
evaporating the solvent from the psychoactive alkaloid liquid to obtain a dephosphorylated psychoactive alkaloid extract comprising psychoactive alkaloid that is psilocin, bufotenine, bufotenidine, norpsilocin, 4-hydroxytryptamine, N,N,N-trimethyl-4-hydroxytryptamine or any combination selected therefrom; and
mixing the dephosphorylated psychoactive alkaloid extract with a mucoadhesive polymer and one or more other excipients including a carrier.

### Claim 22 (depends on 21)

The process of claim 21, wherein the transmucosal psychoactive alkaloid composition consists of, by weight:
1-40% of the dephosphorylated psychoactive alkaloid extract;
1-50% of the mucoadhesive polymer; and
10-95.5% of the one or more other excipients of which 10-65% is the carrier.

### Claim 23 (depends on 21)

The process of claim 21, wherein the acidified solvent has a pH ranging from 0.5-3.5.

### Claim 24 (depends on 21)

The process of claim 21, comprising:
interrupting the evaporating step when the solvent has been partially evaporated from the psychoactive alkaloid liquid, to result in a concentrated slurry;
measuring a psychoactive alkaloid content in the concentrated slurry;
measuring a dry mass content in the concentrated slurry;
using the psychoactive alkaloid content, the dry mass content and a specified concentration of the psychoactive alkaloid in the transmucosal psychoactive alkaloid composition to determine a quantity of the mucoadhesive polymer and a quantity of the one of more other excipients to add to the concentrated slurry in order to obtain the specified concentration when the solvent is completely evaporated;
performing the second mixing step with the quantity of the mucoadhesive polymer and the quantity of the one of more other excipients, thereby standardizing the concentrated slurry; and
continuing the evaporating step to result in the transmucosal psychoactive alkaloid composition with the specified concentration of the psychoactive alkaloid.

### Claim 25 (depends on 21)

The process of claim 21, comprising adding a binder to the transmucosal psychoactive alkaloid composition.

### Claim 26 (depends on 21)

The process of claim 21, comprising adding a bioavailability agent to the transmucosal psychoactive alkaloid composition.

### Claim 27 (depends on 21)

The process of claim 21, comprising adding a flavour agent to the transmucosal psychoactive alkaloid composition.

### Claim 28 (depends on 21)

The process of claim 21, comprising adding a preservative to the transmucosal psychoactive alkaloid composition.

### Claim 29 (depends on 21)

The process of claim 21, comprising forming a tablet with the transmucosal psychoactive alkaloid composition.
